Samuel A. Bozzette
YOU?
Author Swipe
View article: Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia Open
Importance: Immune dysregulation contributes to poorer outcomes in COVID-19. Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, and…
View article: Treatment of Adults Hospitalized With COVID-19 Pneumonia—Reply
Treatment of Adults Hospitalized With COVID-19 Pneumonia—Reply Open
In Reply We thank Drs Mathew and Feldmann for their comments on the results of ACTIV-1.
View article: Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia
Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia Open
A randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the efficacy of infliximab, abatacept, and cenicriviroc in treating patients hospitalized with COVID-19. The patient's clinical status was assessed …
View article: Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia Open
Importance Immune dysregulation contributes to poorer outcomes in COVID-19. Objective To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, and P…
View article: LB1531B. Administration of the TNF-alpha inhibitor, infliximab, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial
LB1531B. Administration of the TNF-alpha inhibitor, infliximab, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial Open
Background Severe COVID-19 infection is characterized by a dysregulated hyperinflammatory state that contributes to morbidity and mortality. Immunomodulatory therapy has been shown to improve outcomes. We investigated if the TNF-alpha inhi…
View article: LB1531A. Administration of abatacept, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial.
LB1531A. Administration of abatacept, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial. Open
Background Severe COVID-19 infection is characterized by a dysregulated hyperinflammatory state that contributes to morbidity and mortality. Immunomodulatory therapy has been shown to improve outcomes. We investigated if abatacept, CTLA-4-…
View article: Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 Open
Background We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. Methods We conducted a master protocol to investigate im…
View article: Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 Open
Background Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care. Methods We co…
View article: Cost of managing meningitis and encephalitis among infants and children in the United States
Cost of managing meningitis and encephalitis among infants and children in the United States Open
A retrospective cohort study design was used to assess the use and costs of diagnostic tests, medication, and total hospitalization costs for pediatric patients with suspected meningitis/encephalitis who received a lumbar puncture (LP) pro…
View article: Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis Open
Although effective for bacterial lower respiratory tract infections (LRTIs), antibiotic treatment is often incorrectly prescribed for non-bacterial LRTIs. Procalcitonin has emerged as a promising biomarker to diagnose bacterial infections …
View article: Cost of managing meningitis and encephalitis among adult patients in the United States of America
Cost of managing meningitis and encephalitis among adult patients in the United States of America Open
Higher diagnostic and treatment costs are associated with a delayed lumbar puncture procedure, the etiological agent, and the requirement for an intensive care unit stay.
View article: Epidemiology of Meningitis and Encephalitis in the United States, 2011–2014
Epidemiology of Meningitis and Encephalitis in the United States, 2011–2014 Open
Viruses are the most common cause of meningitis and encephalitis in the United States and are treated with antibiotic therapy in the majority of cases. Adjunctive steroid treatment is underutilized in pneumococcal meningitis, where it has …
View article: Epidemiology of Meningitis and Encephalitis in Infants and Children in the United States from 2011 to 2014
Epidemiology of Meningitis and Encephalitis in Infants and Children in the United States from 2011 to 2014 Open
Large epidemiological studies evaluating the etiologies, management decisions and outcomes of infants and children with meningitis and encephalitis in the United States (US) are lacking. Infants (<1 year old) and children (1–17 years) with…